Jazz Pharmaceuticals

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

• Revenue over the four quarters to June 30, 2026: $4.60 billion, up 12% from a year earlier.SEC EDGAR filings (XBRL)
• Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.59 billion, up 25% from a year earlier.SEC EDGAR filings (XBRL)
• Capital expenditure over the four quarters to June 30, 2026: $0.07 billion, up 40% from a year earlier.SEC EDGAR filings (XBRL)
• Share buybacks in the fiscal year to December 31, 2025: $0.13 billion.SEC EDGAR filings (10-K)
• Latest earnings call or results release (August 3, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.90 of 1.Palanor Discourse
• Guidance in the last 90 days: 5 outlook figures raised, 0 lowered, 2 held.Guidance Ledger (8-K results releases)
• Latest annual report (filed February 24, 2026): 3 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
• Insiders were net sellers in Q3 2026: $24.4 million on the open market.SEC Form 4
• 645 institutional managers reported a position at June 30, 2026 (+70 on the quarter before).SEC Form 13F
• H-1B filings certified in Q2 2026: 3 (8 a year earlier).U.S. Department of Labor (OFLC)

Company Posture covers S&P 500 companies.

No bond term sheets or tagged debt on file for Jazz Pharmaceuticals yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

In the news

Headlines that name Jazz Pharmaceuticals, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days

1 headlines

0% positive · 0% negative

90 days

1 headlines

0% positive · 0% negative

• Neutral
  Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'

  cnbc.com · via Marketaux · Oct 9, 2026

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

1. Oct 20, 2026Lobbying
   Lobbying report (AVENUE SOLUTIONS)third_quarter 2026 · $0.1 million
2. Oct 20, 2026Lobbying
   Lobbying report (JAZZ PHARMACEUTICALS, INC.)third_quarter 2026 · $0.6 million
3. Oct 20, 2026Lobbying
   Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)third_quarter 2026 · $0.1 million
4. Oct 19, 2026Lobbying
   Lobbying report (THE NICKLES GROUP, LLC)third_quarter 2026 · $0.1 million
5. Oct 18, 2026Lobbying
   Lobbying report (TIBER CREEK GROUP)third_quarter 2026 · $0.1 million
6. Oct 9, 20268-K
   Director or officer changeItem 5.02
7. Sep 29, 2026Patent
   Patent granted: OREXIN RECEPTOR AGONISTS AND USES THEREOFUS 12747252
8. Sep 23, 20268-K
   Material agreement signedItem 1.01
9. Sep 22, 2026Patent
   Patent granted: USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIESUS 12740992
10. Sep 15, 2026Patent
    Patent granted: METHODS FOR PREPARING LIPOSOMAL FORMULATIONSUS 12734181
11. Aug 31, 20268-K
    Material agreement signedItem 1.01
12. Aug 18, 2026Patent
    Patent granted: USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO STRUCTURAL ABNORMALITIES OF THE BRAINUS 12708632
13. Aug 10, 20268-K
    Material agreement signedItem 1.01
14. Jul 24, 20268-K
    Shareholder vote resultsItem 5.07
15. Jul 21, 2026Lobbying
    Lobbying report (TARPLIN, DOWNS & YOUNG, LLC)second_quarter 2026 · $0.1 million
16. Jul 20, 2026Lobbying
    Lobbying report (JAZZ PHARMACEUTICALS, INC.)second_quarter 2026 · $0.5 million
17. Jul 20, 2026Lobbying
    Lobbying report (AVENUE SOLUTIONS)second_quarter 2026 · $0.1 million
18. Jul 14, 2026Patent
    Patent granted: USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIESUS 12678450
19. Jun 30, 2026Private credit
    Loans held by business development companies (Jazz Pharmaceuticals (AKA FINANCING LUX SARL))$3.1 million at cost
20. May 29, 20268-K
    Director or officer changeItem 5.02
21. Feb 24, 202610-K
    Annual report (10-K)3 risk factors added, 0 removed
22. Oct 28, 20258-K
    Director or officer changeItem 5.02
23. Jul 25, 20258-K
    Shareholder vote resultsItem 5.07
24. Jul 10, 20258-K
    Director or officer changeItem 5.02
25. Apr 8, 20258-K
    Material agreement signedItem 1.01
26. Mar 5, 20258-K
    Material agreement signedItem 1.01
27. Mar 5, 20258-K
    Material agreement signedItem 1.01
28. Feb 26, 202510-K
    Annual report (10-K)3 risk factors added, 1 removed
29. Dec 16, 20248-K
    Director or officer changeItem 5.02
30. Nov 26, 20248-K
    Material agreement signedItem 1.01
31. Feb 28, 202410-K
    Annual report (10-K)0 risk factors added, 1 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

Identity

SEC CIK

1232524

Wikidata

Q16255113